uniQure Announces Leadership Promotions and Executive Transition Lexington, MA and Amsterdam, the Netherlands

uniQure Announces Leadership Promotions

and Executive Transition

MA and Amsterdam, the Netherlands, August 20, 2019 - uniQure N.V. (NASDAQ:

QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced

the promotions of Sander van Deventer, M.D., Ph.D., to Executive Vice President,

Research and Product Development, and Alex Kuta, Ph.D., to Executive Vice President,

Operations, effective immediately. As a result of these changes, the Company is eliminating the Chief Operating Officer role,

and Scott McMillan, Ph.D., will be retiring from uniQure.

"With the promotions of Sander and

Alex, we are recognizing the demonstrated track-records and exceptional leadership that each has provided as we advance uniQure's

pipeline of novel gene therapies," stated Matt Kapusta, chief executive officer of uniQure. "As an original founder

of uniQure, Sander is a renowned industry expert who has developed an exceptional research team and expanded our proprietary pipeline

of investigational AAV gene therapies. Alex has spearheaded and achieved remarkable regulatory successes for our hemophilia and

Huntington's disease programs. We very much look forward to their continued contributions as we progress AMT-061 for the

treatment of hemophilia B towards our planned regulatory submissions and expect to advance AMT-130 into the clinic for the treatment

of Huntington's disease. I also would like to thank Scott for his important contributions to uniQure over the past two years.

Scott has played an important role in significantly strengthening our industry-leading CMC capabilities, and I wish him all the

best in the future."

In Dr. van Deventer's new role as

Executive Vice President, Research and Product Development, he is responsible for the Company's gene therapy research activities,

as well as nonclinical development, process development, analytical development and vector development. Dr. van Deventer will continue

to serve as General Manager of uniQure's Amsterdam research and technology center of excellence. In Dr. Kuta's new

role as Executive Vice President, Operations, he is responsible for global quality and regulatory affairs, as well as GMP manufacturing

at uniQure's state-of-the-art facility in Lexington, Massachusetts.

Dr. van Deventer joined

uniQure as Chief Scientific Officer and General Manager, Amsterdam in August 2017 and is a leading pioneer in the biotechnology

industry and in the field of gene therapy. He was a co-founder of uniQure's predecessor Amsterdam Molecular Therapeutics (AMT)

in 1998 and previously served on uniQure's board of directors. Dr. van Deventer is currently Operating Partner at Forbion

Capital partners and Professor of Translational Gastroenterology at Leiden University Medical Center. He also serves as member

of the Board for Hookipa Pharma Inc. in Vienna, Austria. Dr. van Deventer is a trained internist and board-certified gastroenterologist.

He received a Ph.D. from the University of Amsterdam.

uniQure in January 2017 as Senior Vice President, Regulatory Affairs with more than 30 years in the biotechnology field. His previous

experiences include senior roles at EMD Serono, AMAG Pharmaceuticals and Genzyme Corporation, where Dr. Kuta served for 15 years

in regulatory leadership positions of increasing responsibility. Prior to joining industry, he was Chief of the Cytokine and Gene

Therapy Branch in the Center for Biologics at FDA. Dr. Kuta has also served as a member of the BIO Regulatory Affairs Leadership

Committee, Cell and Gene Therapy Working Group and the ICH Gene Therapy Working Group. Dr. Kuta holds a Bachelor of Science degree

from Saint John's University and a Ph.D. from Chicago Medical School at Rosalind Franklin U-Med & Science. He conducted his

post-doctoral studies at the National Cancer Institute/ National Institutes of Health.

uniQure is delivering on the promise of

gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology

platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, hemophilia A, Huntington's

disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

uniQure Forward-Looking Statements

This press release contains forward-looking

statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by

terms such as "anticipate," "believe," "could," "estimate," "expect," "goal,"

"intend," "look forward to", "may," "plan," "potential," "predict,"

"project," "should," "will," "would" and similar expressions. Forward-looking statements

are based on management's beliefs and assumptions and on information available to management only as of the date of this press

release. These forward-looking statements include, but are not limited to, our ability to file any planned regulatory submissions

for AMT-061 or any product, our ability to advance AMT-130 into the clinic for the treatment of Huntington's disease, our

ability to achieve any of our other planned near term or other milestones, the risk of cessation, delay or lack of success of any

of our ongoing or planned clinical studies, and/or the development and regulatory approval of our product candidates. Our actual

results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without

limitation, risks associated with our and our collaborators' clinical development activities, clinical results, collaboration

arrangements, corporate reorganizations and strategic shifts, regulatory oversight, product commercialization and intellectual

property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in

uniQure's Quarterly Report on Form 10-Q filed on July 29, 2019. Given these risks, uncertainties and other factors, you should

not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements,

even if new information becomes available in the future.